Secukinumab, a engineered antibody , represents a significant advance in the treatment of inflammatory diseases . Its primary mechanism of function involves specifically inhibiting Interleukin-17A , a cytokine linked in the development of conditions like psoriasis joint disease and psoriasis . By disrupting the IL-17A , Secukinumab demonstrates a s

MEDI-528, now recognized as enokiizumab , represents a novel treatment targeting the IGF1R, a crucial protein implicated in several epidermal conditions . Early clinical data suggest significant efficacy for the management of moderate to severe atopic dermatitis , particularly in patients who have not benefited from existing remedies. This monoclon